Objective To compare the two anthropometric standards for screening of overweight and cardio-metabolic risk in 6–10-year-old children.Subjects and methods This cross-sectional study included 175 subjects attending the Referral Center for the Treatment of Children and Adolescents in Campos, Rio de Janeiro. They were classified according to CDC and WHO BMI z scores as normal-weight (z-score > –1 and < 1), overweight (z-score ≥ 1 and < 2) or obese (z-score ≥ 2). Sensitivities and specificities in predicting systolic (SBP), diastolic (DBP) blood pressure and homeostatic model assessment insulin resistance index (HOMA-IR) alterations were calculated.Results There was a major difference in 11 children who rated overweight by the CDC but were reclassified as obese by the WHO. Their mean z-scores for SBP (1.71 ± 1.54), DBP (2.64 ± 1.83) and HOMA-IR (1.84 ± 0.98) were higher than those classified as overweight by both references (SBP = 0.49 ± 1.34, p < 0.023, DBP = 1.45 ± 0.97, p < 0.04 and HOMA = 1.24 ± 0.67, p < 0.04), but were similar to those classified as obese by both criteria (SBP = 1.25 ± 2.04, p = 0.60, DBP = 1.94 ± 1.19, p = 0.50 and HOMA = 2.09 ± 1.12, p = 0.76).Conclusion the 2007 WHO reference was the most sensitive in screening for overweight and alterations in blood pressure and HOMA-IR in 6–10-year-old children. Arch Endocrinol Metab. 2015;59(3):220-5

A síndrome metabólica (SM) tem gerado enormes controvérsias, a iniciar-se pela terminologia. O próprio autor que sugeriu o termo, Gerald Reaven, recomenda que não o utilizemos, porque, como a síndrome é um apanhado de alterações metabólicas e três dessas alterações podem defini-la, fica sempre difícil saber-se a que conjunto de alterações estamos nos referindo quando conotamos o termo SM. Em crianças, a complicação é ainda maior, já que se fazem diferentes adaptações aos critérios propostos para adultos. De qualquer forma, independentemente da terminologia, os riscos cardiovasculares são bem estabelecidos e fica cada vez mais claro que as crianças, já em tenra idade, podem começar a ter alterações metabólicas preditivas de problemas mais sérios futuramente. Assim, o papel do endocrinologista pediátrico e do pediatra geral é de investigar essas crianças, especialmente se portadoras de sobrepeso ou obesidade, para detectar precocemente e intervir em condições que podem ser prevenidas na vida adulta. Essa é uma nova visão de uma abordagem pediátrica preventiva de problemas que, usualmente, só são diagnosticados em vida adulta. Nesta revisão, abordamos os aspectos de definição, epidemiologia, fisiopatologia e de complicações da SM em crianças e adolescentes.

Metabolic syndrome (MS) has been a condition involved in considerable controversy, starting with the terminology. Gerald Reaven himself, the author who proposed the term MS, advised against the use of this terminology because the definition implies in at least three metabolic alterations, and it is never clear to which group of alterations we are referring to when we say that a patient has MS. In children, the problem is even more complicated, since there are many different adaptations to the criteria used in adults. On the other hand, independent of the terminology, cardiovascular risks are well-established and it is very clear that even children may present metabolic disturbances which predict future metabolic problems. The role of the pediatric endocrinologist or the general pediatrician is to investigate, especially in overweight/obese children, conditions that if treated early, may prevent future complications that today, unfortunately, are being diagnosed only in adult life. In this review, we discuss problems on the definition, epidemiology, pathophysiology, and complications of MS in children and adolescents.

OBJETIVO: Avaliar a sensibilidade insulínica e o perfil metabólico em portadoras de SOP com peso normal e sobrepeso/obesas. MATERIAL E MÉTODOS: Foram avaliadas, retrospectivamente, 49 pacientes, entre 18 e 45 anos, divididas em 2 grupos, conforme o índice de massa corporal (IMC): grupo 1 (18,5-24,9 kg/m²) e grupo 2 (25-40 kg/m²). Dados coletados: pressão arterial sistólica (PAS) e diastólica (PAD); valores basais e após TOTG da glicose, insulina, e da relação glicose/insulina; área sob a curva para glicose e insulina; HOMA-IR, HOMA-beta; perfil lipídico; testosterona total (T) e livre (TL). RESULTADOS: Maiores médias de níveis pressóricos, insulina, triglicerídeos, TL e índices de resistência insulínica, além de menores níveis de HDL, foram encontrados no grupo 2. Não houve correlação entre o IMC com nenhum dos dados, nem da TL e dos índices de RI com o perfil lipídico. CONCLUSÕES: A obesidade está associada a maior prevalência de RI e DM na SOP, independentemente da história familiar de DM. A ausência de correlação entre os índices de RI e da TL com o perfil lipídico sugerem que outros fatores, como os ácidos graxos livres (AGL), possam estar envolvidos na patogênese da dislipidemia na SOP.

OBJECTIVE: To evaluate insulin sensitivity and the metabolic features in normal weight and overweight/obese patients with PCOS. SUBJETS AND METHODS: Forty-nine (49) patients from 18 to 45 years were retrospectively evaluated and divided into 2 groups, according to the body mass index (BMI): group 1 (18.5-24.9 kg/m²) and group 2 (25-40 kg/m²). Colected data: systolic and dyastolic blood pressure; fasting and after OGTT glucose, insulin and glucose/insulin ratio; area under the curve for glucose and insulin; HOMA-IR and HOMA-beta; lipidic profile; free (FT) and total testosterone (T) levels. RESULTS: Greater averages of pressoric levels, insulin resistance (IR) indices, triglycerides and the FT levels, in adition to lower HDL levels, were found in group 2. Neither correlation between the IMC with none of data nor of the FT and IR indices with the lipid profile were found. CONCLUSIONS: Obesity is associated with insulin resistance and diabetes mellitus in PCOS, independently on familiar history of DM. The absence of correlation between the IR indices and the FT with the lipidic profile suggests that other factors, such as the free fatty acids, can be involved in the pathogenesis of dyslipidemia in PCOS.